The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study.
Administration, Inhalation
Benzyl Alcohols
Bronchodilator Agents
/ adverse effects
Chlorobenzenes
/ adverse effects
Double-Blind Method
Drug Combinations
Humans
Muscarinic Antagonists
/ adverse effects
Primary Health Care
Pulmonary Disease, Chronic Obstructive
/ diagnosis
Quinuclidines
/ adverse effects
Retrospective Studies
Treatment Outcome
United Kingdom
/ epidemiology
chronic obstructive pulmonary disease
electronic medical records
long-acting muscarinic antagonist
long-acting β2-agonist
umeclidinium
umeclidinium/vilanterol
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
Historique:
received:
13
11
2020
accepted:
22
02
2021
entrez:
18
3
2021
pubmed:
19
3
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Umeclidinium bromide (UMEC) and umeclidinium/vilanterol (UMEC/VI) received European approval for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) in 2014. This study examined prescribing patterns, possible off-label prescribing, potential safety-related outcomes and adherence of these medications in routine clinical practice post-approval. This retrospective, multi-database, longitudinal observational study of new users of UMEC, UMEC/VI, or other long-acting bronchodilators (LABD) analyzed data from UK electronic health record databases (primary care cohort), linked to hospital data (linked cohort). Off-label prescribing, safety outcomes (cardiovascular, respiratory, and mortality), treatment patterns, and medication adherence were assessed. In the primary care cohort (new users of UMEC n=3875; UMEC/VI n=2224; other LABD n=32,809), two-thirds of UMEC users were prescribed concomitant inhaled corticosteroids/long-acting β Most new users of UMEC were receiving multiple-inhaler triple therapy. Off-label prescribing was uncommon for new users of UMEC and UMEC/VI. Incidence of cardiovascular and respiratory outcomes was as expected for these drug classes. This study provides evidence that UMEC and UMEC/VI are being prescribed appropriately and their safety profile remains unchanged.
Sections du résumé
BACKGROUND
BACKGROUND
Umeclidinium bromide (UMEC) and umeclidinium/vilanterol (UMEC/VI) received European approval for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) in 2014. This study examined prescribing patterns, possible off-label prescribing, potential safety-related outcomes and adherence of these medications in routine clinical practice post-approval.
METHODS
METHODS
This retrospective, multi-database, longitudinal observational study of new users of UMEC, UMEC/VI, or other long-acting bronchodilators (LABD) analyzed data from UK electronic health record databases (primary care cohort), linked to hospital data (linked cohort). Off-label prescribing, safety outcomes (cardiovascular, respiratory, and mortality), treatment patterns, and medication adherence were assessed.
RESULTS
RESULTS
In the primary care cohort (new users of UMEC n=3875; UMEC/VI n=2224; other LABD n=32,809), two-thirds of UMEC users were prescribed concomitant inhaled corticosteroids/long-acting β
CONCLUSION
CONCLUSIONS
Most new users of UMEC were receiving multiple-inhaler triple therapy. Off-label prescribing was uncommon for new users of UMEC and UMEC/VI. Incidence of cardiovascular and respiratory outcomes was as expected for these drug classes. This study provides evidence that UMEC and UMEC/VI are being prescribed appropriately and their safety profile remains unchanged.
Identifiants
pubmed: 33731992
doi: 10.2147/COPD.S291931
pii: 291931
pmc: PMC7956862
doi:
Substances chimiques
Benzyl Alcohols
0
Bronchodilator Agents
0
Chlorobenzenes
0
Drug Combinations
0
GSK573719
0
Muscarinic Antagonists
0
Quinuclidines
0
vilanterol
028LZY775B
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
629-642Informations de copyright
© 2021 Requena et al.
Déclaration de conflit d'intérêts
GR is an employee of GSK and holds stocks/shares in GSK. DD, REG, and RW are employees of CPRD. JKQ has received funds from The Health Foundation, MRC, GSK, Bayer, Boehringer Ingelheim, British Lung Foundation (Asthma UK), IQVIA, Chiesi, AstraZeneca, Insmed, and Asthma UK, and grants and personal fees from GSK, Boehringer Ingelheim, AstraZeneca, Bayer, and Insmed. JMP was an employee of GSK at the time of the study and holds stocks/shares in GSK. The authors report no other conflicts of interest in this work.
Références
Int J Chron Obstruct Pulmon Dis. 2019 Aug 01;14:1721-1737
pubmed: 31534326
Respir Med. 2019 Jun;152:37-43
pubmed: 31128608
Int J Chron Obstruct Pulmon Dis. 2016 Apr 07;11:719-30
pubmed: 27103795
Chest. 2017 Jan;151(1):60-67
pubmed: 27554300
Respir Med. 2014 Dec;108(12):1752-60
pubmed: 25458157
Clin Epidemiol. 2016 Nov 21;8:771-782
pubmed: 27920578
Int J Chron Obstruct Pulmon Dis. 2019 Jun 06;14:1251-1265
pubmed: 31239659
Thorax. 2008 Sep;63(9):831-8
pubmed: 18728206
Drugs. 2016 Mar;76(3):343-61
pubmed: 26755180
Chest. 2019 Jun;155(6):1158-1165
pubmed: 30922950
Respir Med. 2013 Oct;107(10):1538-46
pubmed: 23830094
BMJ Open Respir Res. 2018 Oct 25;5(1):e000339
pubmed: 30397486
Eur Respir J. 2014 Jan;43(1):72-81
pubmed: 23949963
J Asthma. 2006 Jan-Feb;43(1):75-80
pubmed: 16448970
Respir Med. 2013 Oct;107(10):1481-90
pubmed: 23643487
Int J Chron Obstruct Pulmon Dis. 2015 Sep 02;10:1753-67
pubmed: 26366068
Int J Chron Obstruct Pulmon Dis. 2019 Sep 04;14:2047-2060
pubmed: 31564852
PLoS One. 2016 Mar 09;11(3):e0151357
pubmed: 26959820
Pulm Pharmacol Ther. 2019 Aug;57:101802
pubmed: 31096036
BMJ Open. 2012 May 22;2(3):
pubmed: 22619266